Rapid Medical Countermeasure Response to Infectious Diseases Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary (2016) / Chapter Skim
Currently Skimming:
E Biosketches of Invited Speakers and Facilitators
E Biosketches of Invited Speakers and Facilitators
Pages 129-156
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 129... ...
government, the company is dedicated to the development, manufacture, and delivery of a portfolio of medical countermeasures that address biological and chemical threats, including anthrax, botulinum, smallpox, and chemical agents as well as emerging infectious diseases. The company also develops and commercializes therapeutics and other specialty products for hospitals and clinics to address hematology/oncology, transplantation, infectious disease, and autoimmune disorders.
|
From page 130... ...
. The Influenza Division is responsible for preparing the nation for influenza pandemics and coordinating production, acquisition, and delivery of medical countermeasures during a pandemic response.
|
From page 131... ...
, and clinical trials. Peter Daszak, Ph.D., is President of EcoHealth Alliance, a U.S.-based organization that conducts research and outreach programs on global health, conservation and international development.
|
From page 132... ...
committee on global surveillance for emerging zoonoses, the National Research Council (NRC) committee on the future of veterinary research, the International Standing Advisory Board of the Australian Biosecurity CRC; and has advised the Director for Medical Preparedness Policy on the White House National Security Staff on global health issues.
|
From page 133... ...
Mr. Dunn assumed his current role at MCS as an assistant product manager in June 2013.
|
From page 134... ...
His vision is for academic health sciences centers to lead the transformation of medicine through innovation, translation, and globalization. Leading this vision at Duke, he and his colleagues developed the Duke Translational Medicine Institute, the Duke Global Health Institute, the Duke-National University of Singapore Graduate Medical School, and the Duke Institute for Health Innovation.
|
From page 135... ...
Jeremy Farrar, Ph.D., is director of the Wellcome Trust, a global charitable foundation dedicated to achieving extraordinary improvements in health by supporting the brightest minds. Before joining the Trust he was director of the Oxford University Clinical Research Unit in Vietnam, where his research interests were in infectious diseases, tropical health and emerging infections.
|
From page 136... ...
Dr. Feinberg also founded and served as the medical director of the Hope Clinic of the Emory Vaccine Center -- a clinical research facility devoted to the clinical evaluation of novel vaccines for HIV and other infectious diseases, and in basic research studies focused on revealing fundamental aspects of the pathogenesis of AIDS.
|
From page 137... ...
from Duke University. He trained in internal medicine at Johns Hopkins University and infectious disease at the NIAID, where he was a member of the Laboratory of Clinical Investigation from 1979 to 1989.
|
From page 138... ...
Prior to joining Critical Path Institute, she spent 11 years within the Antibacterial Research and Development Unit with Pfizer Global Research and Development. She was the research project leader for multiple antibacterial drug development programs.
|
From page 139... ...
Previously, he served as Director for Medical Preparedness Policy on the White House National Security Staff, where he worked on a wide array of issues related to medical countermeasures development, the 2009 H1N1 pandemic, and pandemic preparedness more broadly. In 2005–2006, he served as Director for Biodefense Policy on the White House Homeland Security Council and was a principal author of the National Strategy for Pandemic Influenza Implementation Plan.
|
From page 140... ...
CDR Jones has made significant strides toward developing national security policy and coordinating interagency research and development policies in the areas of chemical and biological defense. She has led or co-led the development of the National Biological Response and Recovery Science and Technology Roadmap; National Biosurveillance Science and Technology Roadmap; National Strategy for Chemical, Biological, Radiological, Nuclear, and Explosives Standards; National Non-Traditional Chemical Agent Research, Development, Testing, and Eval-uation Strategy; National Strategy for Biosurveillance; and United States Government Policy for Oversight of Dual Use Research of Concern.
|
From page 141... ...
Katz has adjunct appointments at Emory University in the Departments of Microbiology and Immunology and Pathology, and is an adjunct member of the graduate faculty in the Immunology and Molecular Pathogenesis Program of the Division of Biological and Biomedical Sciences. She also serves as an associate editor for the International Society for Influenza and Other Respiratory Virus Diseases.
|
From page 142... ...
The goals of BARDA's Broad Spectrum Antimicrobials program are to enable the U.S. government to acquire medical countermeasures (MCMs)
|
From page 143... ...
Larsen served as a senior science and technology manager at the Joint Science and Technology Office for Chemical and Biological Defense within the Defense Threat Reduction Agency. In that position he managed an ~$50M applied research program aimed at the development of medical therapeutics against viral, bacterial, and toxin threat agents.
|
From page 144... ...
Meghan Majorowski, M.Sc., leads the Global Health practice at FSG, a mission driven consulting firm committed to reimaging social change that serves foundations, businesses, non profits and governments around the world. She brings nearly 15 years of experience in strategic and tactical consulting as well as management of development programs in emerging economies.
|
From page 145... ...
From 2002 to 2010, she led MCM policy and strategy efforts for HHS, establishing the inaugural Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan, which provided the framework for priority setting and a roadmap for the allocation of the $5.6 billion Special Reserve Fund provided under Project BioShield from FY04 to FY13. The requirements for chemical, biological, radiological, and nuclear MCMs established under her leadership have provided the foundation for the HHS product development pipeline at NIH and BARDA, and for the BioShield acquisition programs.
|
From page 146... ...
He has led numerous investigations of outbreaks of international importance, including foodborne diseases, the association of tampons and toxic shock syndrome, the transmission of hepatitis B in health care settings, and HIV infection in health care workers. In addition, his team conducted many studies on infectious diseases in child-care settings, vaccine-preventable diseases (particularly Haemophilus influenzae type b and hepatitis B)
|
From page 147... ...
and has served on CDC's National Center for Infectious Diseases Board of Scientific Counselors.
|
From page 148... ...
She was a professor of public health and director of the Johns Hopkins University Center for Civilian Biodefense Studies at the Johns Hopkins Bloomberg School of Public Health, which was the first academic center devoted to biosecurity policy and practices, and played a major role in defining the nature and consequences of major biological threats, both natural and deliberate.
|
From page 149... ...
Gerald W Parker, Jr., D.V.M., Ph.D, M.S., joined the Texas A&M Health Science Center in 2013 as vice president for public health preparedness and response, and as Principal Investigator for the Texas A&M Center for Innovation in Advanced Development and Manufacturing, a public–private partnership with the HHS designed to enhance the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza, and chemical, biological, radiological, and nuclear threats.
|
From page 150... ...
He is a member of the board of directors of the Infectious Diseases Society of America and chairs the Pandemic Influenza and Bio-emergencies Task Force. He is also a member of the Board of Scientific Counselors of the Director of the Office of Infectious Diseases at CDC and has served as a member of the National Biodefense Science Board and the National Vaccine Advisory Board.
|
From page 151... ...
Dr. Robinson was recruited by HHS from the vaccine industry in 2004 to establish a program with scientific and technical experts to implement the strategic plans and policies for MCMs outlined in the National Strategy for Pandemic Influenza.
|
From page 152... ...
Dr. Robinson also serves on WHO international expert teams on pandemic influenza vaccines.
|
From page 153... ...
He is an adjunct assistant professor at Rollins School of Public Health, Emory University, where he has been the lead instructor of two epidemiology courses since 2000, and he is on the faculty council. He is on the HHS Executive Enterprises Committee, the HHS Public Health Emergency Medical Countermeasures Enterprise Emerging Infectious Disease Working Group, and the Program Committee of the Infectious Diseases Society of America.
|
From page 154... ...
He led the development and implementation of the National Strategy for Pandemic Influenza, as well as presidential directives on medical countermeasures
|
From page 155... ...
He supported international efforts to eliminate Syrian and Libyan chemical weapons and to strengthen global health security. Prior to his appointment by Obama in 2009, he spent 13 years as an adviser for threat reduction policy in the Office of the Secretary of Defense.
|
From page 156... ...
His primary responsibilities include oversight of the discovery and development of the proprietary formulation of phosphorodiamidate morpholino oligomers as effective antiviral and antibacterial agents, and of the strategic alliances for the development of those products. Current applications of the antisense oligomers include medical countermeasures for filovirus infections, including Ebola and Marburg viruses and pandemic influenza A, and agents effective against a variety of multidrug-resistant bacteria.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.